↓ Skip to main content

Dove Medical Press

Article Metrics

New developments in the management of head and neck cancer – impact of pembrolizumab

Overview of attention for article published in Therapeutics and Clinical Risk Management, February 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (64th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter
2 tweeters
patent
1 patent

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
115 Mendeley
Title
New developments in the management of head and neck cancer – impact of pembrolizumab
Published in
Therapeutics and Clinical Risk Management, February 2018
DOI 10.2147/tcrm.s125059
Pubmed ID
Authors

Khalil Saleh, Roland Eid, Fady GH Haddad, Nadine Khalife-Saleh, Hampig Raphaël Kourie

Abstract

Head and neck squamous cell carcinoma (HNSCC), a heterogeneous group of upper aerodigestive tract malignancies, is the seventh most common cancer worldwide. Tobacco use and alcohol consumption were the most identified risk factors of HNSCC. However, human papilloma virus, a sexually transmitted infection, has been determined as another primary cause of HNSCC. Early-stage disease is treated with surgery or radiotherapy. Recurrent or metastatic HNSCC is associated with poor prognosis with a median overall survival of 10 months. The EXTREME protocol is commonly used in first-line setting. Recently, pembrolizumab, an anti-programmed death-1 agent, has been approved by the US Food and Drug Administration for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. It demonstrated a durable objective response rate with a good safety profile and quality of life. Many ongoing trials are evaluating the use of pembrolizumab for the treatment of HNSCC in various indications such as adjuvant and neoadjuvant setting, maintenance and recurrent disease, alone or in combination with chemotherapy, radiation and targeted therapy. Finding those biomarkers predictive of response to immune checkpoints inhibitors has been a major concern. However, markers have been identified, such as PD-L1 expression, human papilloma virus infection, interferon-γ signature score, microsatellite instability and neoantigen production.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 115 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 115 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 14 12%
Researcher 14 12%
Student > Bachelor 11 10%
Student > Master 11 10%
Student > Ph. D. Student 9 8%
Other 30 26%
Unknown 26 23%
Readers by discipline Count As %
Medicine and Dentistry 31 27%
Unspecified 14 12%
Biochemistry, Genetics and Molecular Biology 12 10%
Nursing and Health Professions 8 7%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Other 13 11%
Unknown 31 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 July 2020.
All research outputs
#5,379,717
of 18,081,658 outputs
Outputs from Therapeutics and Clinical Risk Management
#266
of 1,125 outputs
Outputs of similar age
#100,765
of 284,851 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#9
of 25 outputs
Altmetric has tracked 18,081,658 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 1,125 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,851 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.